NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Ipsen (EPA: IPN)
IPN Technical Analysis
2
As on 1st Nov 2017 IPN Share Price closed @ 104.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 99.11 & Strong Sell for SHORT-TERM with Stoploss of 113.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IPN Share Price
Open | 104.00 | Change | Price | % |
High | 105.75 | 1 Day | 0.95 | 0.92 |
Low | 103.95 | 1 Week | 0.00 | 0.00 |
Close | 104.75 | 1 Month | -9.55 | -8.36 |
Volume | 65090 | 1 Year | 43.44 | 70.85 |
52 Week High 129.85 | 52 Week Low 61.12 |
EPA France Most Active Stocks
MT | 4.53 | 12.97% |
MT | 4.53 | 12.97% |
GSZ | 17.56 | 3.97% |
BRS | 12.00 | 0.00% |
VK | 4.72 | 0.43% |
ALALO | 0.04 | 0.00% |
CS | 26.31 | 1.47% |
TEC | 67.40 | 0.40% |
ACA | 14.98 | 0.00% |
ALAUP | 0.20 | -13.04% |
EPA France Top Gainers Stocks
EPA France Top Losers Stocks
IPN Daily Charts |
IPN Intraday Charts |
Whats New @ Bazaartrend |
IPN Free Analysis |
|
IPN Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
RESISTANCE | 106.42 |
RESISTANCE | 105.73 |
SUPPORT | 103.77 |
SUPPORT | 103.08 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
IPN Target for Month January
4th UP TARGET | 137.92 |
3rd UP TARGET | 127.07 |
2nd UP TARGET | 120.37 |
1st UP TARGET | 113.66 |
1st DOWN TARGET | 94.54 |
2nd DOWN TARGET | 87.83 |
3rd DOWN TARGET | 81.13 |
4th DOWN TARGET | 70.28 |
IPN Weekly Target
4th UP TARGET | 0.00 |
3rd UP TARGET | 0.00 |
2nd UP TARGET | 0.00 |
1st UP TARGET | 0.00 |
1st DOWN TARGET | 0.00 |
2nd DOWN TARGET | 0.00 |
3rd DOWN TARGET | 0.00 |
4th DOWN TARGET | 0.00 |
IPN Target for Year 2021
4th UP TARGET | 0 |
3rd UP TARGET | 0 |
2nd UP TARGET | 0 |
1st UP TARGET | 0 |
1st DOWN TARGET | 0 |
2nd DOWN TARGET | 0 |
3rd DOWN TARGET | 0 |
4th DOWN TARGET | 0 |
Ipsen ( EPA France Symbol : IPN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IPN Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | Healthcare | |
Industry | Drugs - Generic | |
Offical website | > echo $website ; ?> |
IPN Address
![]() |
65, quai Georges Gorse Cedex Boulogne-Billancourt, 92650 France Phone: 33 1 58 33 50 00 Fax: 33 1 58 33 50 01 |
IPN Latest News
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The companyÂ’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service